Grant Number:	5R01CA261898-04 Interpret this number
Primary Investigator:	Burridge, Paul
Organization:	Northwestern University At Chicago
Project Title:	Predicting and Preventing Chemotherapy-Induced Cardiotoxicity in African American Children
Fiscal Year:	2024

Project Summary Doxorubicin is a member of the anthracycline group of chemotherapy drugs prescribed to approximately 60% of pediatric cancer patients suffering with sarcomas, blastomas, leukemia, and lymphoma. Although doxorubicin is highly effective in these patients, ~16% of pediatric patients suffer doxorubicin-induced cardiotoxicity (DIC) which can lead to heart failure requiring heart transplant. Our recent work has shown that DIC is 2.5x more prevalent in African American (AA) survivors of childhood cancer. Despite more than 50 years of research in this field, there is still, at present, little potential for either predicting or preventing DIC. There is an obvious need for novel and innovative approaches to overcome this hurdle. Candidate gene and genome-wide association studies, predominantly in Europeans, have identified >100 single nucleotide polymorphisms (SNPs) that are statistically correlated with DIC, yet experimental validation has not been feasible due to the difficulty in isolating and culturing human cardiomyocytes in vitro. In our recent work, we showed that patient-specific human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are efficient predictors of a patient’s likelihood of developing DIC, confirming for the first time that there is a genomic basis to DIC. Here, we hypothesize that hiPSC-CMs can be utilized in three different modalities to study genetic variants associated with DIC in AA survivors: firstly, to discover novel predictive SNPs; secondly, to validate SNPs; and thirdly, to examine the modulated pathways and determine genotype-specific cardioprotective methodologies. In Aim 1, we will generate hiPSC from 100 AA adult survivors of childhood cancer with diverse biological covariates who were exposed to doxorubicin assess their response to doxorubicin in vitro to validate our previous findings and verify the power of this tool. In Aim 2, we will use these 100 patient-specific lines to identify drug response differential expression, splicing and chromatin accessibility quantitative trait loci (deQTL, dsQTL and dcaQTL), assessing biological covariates such as doxorubicin dose, age at cancer diagnosis, attained age, sex, BMI, radiotherapy (other than involving chest), and cancer diagnosis both individually and combined. We will then validate these variants with genome editing, and mechanistically examine pathways causative to DIC susceptibility concentrating on genes with known roles in cardiomyopathy, cardioprotection, and doxorubicin metabolism. We will then use the discoveries above to discover/repurpose genome-informed cardioprotective drugs to prevent DIC in a genotype-specific manner. In Aim 3, we will build a risk prediction model for DIC among AA survivors incorporating clinical risk factors and functionally assessed genetic variants above, evaluate its prediction performance, validate it in independent AA survivors, and implement it in a web-based and user- friendly tool for broader clinical and research use. In summary, this work will deliver us the genetic rationale for why AA survivors experience DIC and provide 1, fully human validated SNP data for clinical application through a user-friendly tool, and 2, novel cardioprotective pathways that can be targeted to protect against DIC.




Independent compartmentalization of functional, metabolic, and transcriptional maturation of hiPSC-derived cardiomyocytes.
Authors: Fetterman K.A. , Blancard M. , Lyra-Leite D.M. , Vanoye C.G. , Fonoudi H. , Jouni M. , DeKeyser J.L. , Lenny B. , Sapkota Y. , George A.L. , et al. .
Source: Cell Reports, 2024-04-27 00:00:00.0; 43(5), p. 114160.
EPub date: 2024-04-27 00:00:00.0.
PMID: 38678564
Related Citations

Trans-Ancestral Genetic Risk Factors for Treatment-Related Type 2 Diabetes Mellitus in Survivors of Childhood Cancer.
Authors: Im C. , Neupane A. , Baedke J.L. , Lenny B. , Delaney A. , Dixon S.B. , Chow E.J. , Mostoufi-Moab S. , Yang T. , Richard M.A. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2024-04-23 00:00:00.0; , p. JCO2302281.
EPub date: 2024-04-23 00:00:00.0.
PMID: 38652878
Related Citations

St. Jude Survivorship Portal: sharing and analyzing large clinical and genomic datasets from pediatric cancer survivors.
Authors: Matt G.Y. , Sioson E. , Shelton K. , Wang J. , Lu C. , Zaldivar Peraza A. , Gangwani K. , Paul R. , Reilly C. , Acić A. , et al. .
Source: Cancer Discovery, 2024-04-09 00:00:00.0; , .
EPub date: 2024-04-09 00:00:00.0.
PMID: 38593228
Related Citations

Nilotinib-induced alterations in endothelial cell function recapitulate clinical vascular phenotypes independent of ABL1.
Authors: Pinheiro E.A. , DeKeyser J.M. , Lenny B. , Sapkota Y. , Burridge P.W. .
Source: Scientific Reports, 2024-03-26 00:00:00.0; 14(1), p. 7123.
EPub date: 2024-03-26 00:00:00.0.
PMID: 38532120
Related Citations

Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes.
Authors: Fonoudi H. , Jouni M. , Cejas R.B. , Magdy T. , Blancard M. , Ge N. , Shah D.A. , Lyra-Leite D.M. , Neupane A. , Gharib M. , et al. .
Source: Jacc. Cardiooncology, 2024 Feb; 6(1), p. 38-50.
EPub date: 2024-01-23 00:00:00.0.
PMID: 38510289
Related Citations

Anthracycline Toxicity: Light at the End of the Tunnel?
Authors: Cejas R.B. , Petrykey K. , Sapkota Y. , Burridge P.W. .
Source: Annual Review Of Pharmacology And Toxicology, 2024-01-23 00:00:00.0; 64, p. 115-134.
EPub date: 2023-10-03 00:00:00.0.
PMID: 37788492
Related Citations

Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline-Induced Cardiomyopathy - A COG-ALTE03N1 Report.
Authors: Singh P. , Shah D.A. , Jouni M. , Cejas R.B. , Crossman D.K. , Magdy T. , Qiu S. , Wang X. , Zhou L. , Sharafeldin N. , et al. .
Source: Journal Of The American Heart Association, 2023-10-03 00:00:00.0; 12(19), p. e029954.
EPub date: 2023-09-26 00:00:00.0.
PMID: 37750583
Related Citations

A novel transcription factor combination for direct reprogramming to a spontaneously contracting human cardiomyocyte-like state.
Authors: Romero-Tejeda M. , Fonoudi H. , Weddle C.J. , DeKeyser J.M. , Lenny B. , Fetterman K.A. , Magdy T. , Sapkota Y. , Epting C.L. , Burridge P.W. .
Source: Journal Of Molecular And Cellular Cardiology, 2023-07-06 00:00:00.0; 182, p. 30-43.
EPub date: 2023-07-06 00:00:00.0.
PMID: 37421991
Related Citations

Nutritional requirements of human induced pluripotent stem cells.
Authors: Lyra-Leite D.M. , Copley R.R. , Freeman P.P. , Pongpamorn P. , Shah D. , McKenna D.E. , Lenny B. , Pinheiro E.A. , Weddle C.J. , Gharib M. , et al. .
Source: Stem Cell Reports, 2023-06-13 00:00:00.0; 18(6), p. 1371-1387.
PMID: 37315525
Related Citations

Trans-ancestral genetic study of diabetes mellitus risk in survivors of childhood cancer: a report from the St. Jude Lifetime Cohort and the Childhood Cancer Survivor Study.
Authors: Im C. , Neupane A. , Baedke J.L. , Delaney A. , Dixon S.B. , Chow E.J. , Mostoufi-Moab S. , Richard M.A. , Gramatges M.M. , Lupo P.J. , et al. .
Source: Medrxiv : The Preprint Server For Health Sciences, 2023-06-05 00:00:00.0; , .
EPub date: 2023-06-05 00:00:00.0.
PMID: 37333357
Related Citations

RBL2 Regulates Cardiac Sensitivity to Anthracycline Chemotherapy.
Authors: Xia P. , Chen J. , Sapkota Y. , Scott E.N. , Liu Y. , Hudson M.M. , Rassekh S.R. , Carleton B.C. , Ross C.J.D. , Chow E.J. , et al. .
Source: Jacc. Cardiooncology, 2023 Jun; 5(3), p. 360-373.
EPub date: 2023-03-28 00:00:00.0.
PMID: 37397090
Related Citations

Genetic risk score enhances the risk prediction of severe obesity in adult survivors of childhood cancer.
Authors: Sapkota Y. , Qiu W. , Dixon S.B. , Wilson C.L. , Wang Z. , Zhang J. , Leisenring W. , Chow E.J. , Bhatia S. , Armstrong G.T. , et al. .
Source: Nature Medicine, 2022-07-25 00:00:00.0; , .
EPub date: 2022-07-25 00:00:00.0.
PMID: 35879615
Related Citations

Underdiagnosis and Undertreatment of Modifiable Cardiovascular Risk Factors Among Survivors of Childhood Cancer.
Authors: Chow E.J. , Chen Y. , Armstrong G.T. , Baldwin L.M. , Cai C.R. , Gibson T.M. , Hudson M.M. , McDonald A. , Nathan P.C. , Olgin J.E. , et al. .
Source: Journal Of The American Heart Association, 2022-06-21 00:00:00.0; 11(12), p. e024735.
EPub date: 2022-06-08 00:00:00.0.
PMID: 35674343
Related Citations

A novel locus on 6p21.2 for cancer treatment-induced cardiac dysfunction among childhood cancer survivors.
Authors: Sapkota Y. , Ehrhardt M.J. , Qin N. , Wang Z. , Liu Q. , Qiu W. , Shelton K. , Shao Y. , Plyler E. , Mulder H.L. , et al. .
Source: Journal Of The National Cancer Institute, 2022-06-14 00:00:00.0; , .
EPub date: 2022-06-14 00:00:00.0.
PMID: 35698272
Related Citations

Contribution of Genome-Wide Polygenic Score to Risk of Coronary Artery Disease in Childhood Cancer Survivors.
Authors: Sapkota Y. , Liu Q. , Li N. , Bhatt N.S. , Ehrhardt M.J. , Wilson C.L. , Wang Z. , Jefferies J.L. , Zhang J. , Armstrong G.T. , et al. .
Source: Jacc. Cardiooncology, 2022 Jun; 4(2), p. 258-267.
EPub date: 2022-06-21 00:00:00.0.
PMID: 35818558
Related Citations

Pharmacogenomic Screening of Drug Candidates using Patient-Specific hiPSC-Derived Cardiomyocyte High-Throughput Calcium Imaging.
Authors: Blancard M. , Fetterman K.A. , Burridge P.W. .
Source: Methods In Molecular Biology (clifton, N.j.), 2022; 2547, p. 241-253.
PMID: 36068467
Related Citations

Identification of Drug Transporter Genomic Variants and Inhibitors that Protect Against Doxorubicin-Induced Cardiotoxicity.
Authors: Magdy T. , Jouni M. , Kuo H.H. , Weddle C.J. , Lyra-Leite D. , Fonoudi H. , Romero-Tejeda M. , Gharib M. , Javed H. , Fajardo G. , et al. .
Source: Circulation, 2021-12-07 00:00:00.0; , .
EPub date: 2021-12-07 00:00:00.0.
PMID: 34874743
Related Citations

RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy.
Authors: Magdy T. , Jiang Z. , Jouni M. , Fonoudi H. , Lyra-Leite D. , Jung G. , Romero-Tejeda M. , Kuo H.H. , Fetterman K.A. , Gharib M. , et al. .
Source: Cell Stem Cell, 2021-09-14 00:00:00.0; , .
EPub date: 2021-09-14 00:00:00.0.
PMID: 34525346
Related Citations

Cellular model systems to study cardiovascular injury from chemotherapy.
Authors: Fonoudi H. , Burridge P.W. .
Source: Journal Of Thrombosis And Thrombolysis, 2020-10-13 00:00:00.0; , .
EPub date: 2020-10-13 00:00:00.0.
PMID: 33051807
Related Citations

Pluripotent Stem Cell Modeling of Anticancer Therapy-Induced Cardiotoxicity.
Authors: Lyra-Leite D.M. , Burridge P.W. .
Source: Current Cardiology Reports, 2020-06-19 00:00:00.0; 22(8), p. 56.
EPub date: 2020-06-19 00:00:00.0.
PMID: 32562096
Related Citations